Is Durvalumab available in China?

Durvalumab/Infinifer (Durvalumab) has been approved for marketing in China, which provides Chinese patients with an accessible PD-L1 immunotherapy option. However, durvalumab is currently not included in medical insurance and the price is relatively high. Common specifications include 120mg/2.4mL and 500mg/10mL, which are mainly used for unresectable locally advanced small cell lung cancer, non-small cell lung cancer and urothelial cancer. As an imported original drug, its efficacy and safety are consistent with international standards, bringing opportunities for domestic patients with advanced international treatment options.

It is worth noting that there are currently no domestic generic drugs of durvalumab on the market in China. This means that if domestic patients choose to use imrvalumab, they still have to rely on imported drug channels, and the price and accessibility are subject to certain restrictions. Although many domestic biopharmaceutical companies are developing PD-L1 inhibitors and arranging clinical trials for different indications, direct domestic alternatives to durvalumab have not yet been launched. This also reflects the clinical verification and regulatory approval cycles that innovative drugs need to go through during the localization process.

From a market perspective, durvalumab, as a PD-L1 inhibitor, has a clear clinical positioning and internationally recognized efficacy. With the rapid development of the domestic immunotherapy market, it is expected that similar domestic drugs or PD-L1 inhibitors with similar efficacy may appear in the future to reduce the treatment burden on patients. Currently, when doctors select immunotherapy options, they usually take comprehensive consideration into the tumor type, patient's physical condition, economic conditions, and drug availability. Immobilumab is still one of the important treatment options for high-risk advanced lung cancer and urothelial cancer.

In addition, the clinical research and global guideline recommendations of durvalumab also provide reference for domestic application. Although domestic generic drugs have not yet been launched, as pharmaceutical companies accelerate research and development and promote international cooperation, domestic PD-L1 inhibitors are expected to compete with original drugs in the future, bringing more treatment options to patients. Generally speaking, durvalumab is still an imported original drug in China, and its high clinical value has been recognized, but the localization process still takes time.

Reference materials:https://www.imfinzi.com/